GlassScriptPhysician profile
Mikaela M Wallace
NPI 1992298467
$2,036.80
in general payments reported to CMS, 2019-2025
25 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $173 · 2023: $566 · 2024: $516 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $311.09 | 2021-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $275.17 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $227.47 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceuticals, INC. | $182.82 | 2021 | |
| Novo Nordisk INC | $170.54 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $125.49 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $124.47 | 2024 | Freestyle Libre 3 |
| Pfizer INC. | $122.34 | 2023-2025 | |
| Organon LLC | $79.65 | 2021-2025 | Nexplanon |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.06 | 2025 | Caplyta |
| Dexcom, INC. | $49.70 | 2023-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $47.91 | 2024 | Veozah |
| Exact Sciences Corporation | $36.92 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.35 | 2022 | |
| Nabriva Therapeutics, Plc | $22.58 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.16 | 2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Mylan Specialty L.P. | $19.70 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.76 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.19 | 2022 | |
| Si-Bone, INC. | $17.96 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.00 | 2023 | Trintellix |
| Ironshore Pharmaceuticals INC. | $15.90 | 2022 | |
| Lundbeck LLC | $15.41 | 2023 | Rexulti |
| Sanofi Pasteur INC. | $15.02 | 2023 | |
| Genentech USA, INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikaela Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.